3-MeO-PCMo is a dissociative anesthetic drug with structural similarities to phencyclidine (PCP). This substance has been available for purchase online as a designer drug. Notably, its inhibitory effect on the reduction of drebrin cluster density induced by NMDAR stimulation with glutamic acid is comparatively weaker when compared to PCP or 3-MeO-PCP. The half-maximal inhibitory concentration (IC50) values for this effect are as follows: 26.67 μM for 3-MeO-PCMo, 2.02 μM for PCP, and 1.51 μM for 3-MeO-PCP.
What is 3-MeO-PCMo?3-MeO-PCMo is a dissociative anesthetic drug with structural similarities to phencyclidine (PCP). It has gained attention as a designer drug and is sometimes sold online.
How does 3-MeO-PCMo compare to PCP and 3-MeO-PCP?In terms of its inhibitory effect on the reduction of drebrin cluster density caused by NMDAR stimulation with glutamic acid, 3-MeO-PCMo exhibits a weaker effect when compared to PCP and 3-MeO-PCP. The half-maximal inhibitory concentration (IC50) for 3-MeO-PCMo is 26.67 μM, whereas it’s 2.02 μM for PCP and 1.51 μM for 3-MeO-PCP.
Is 3-MeO-PCMo legal?The legal status of 3-MeO-PCMo varies by country and is subject to change. It’s essential to check local laws and regulations regarding this substance.
What are the potential effects of 3-MeO-PCMo?As a dissociative anesthetic, 3-MeO-PCMo may induce altered perceptions, sensory dissociation, and other psychoactive effects. However, the specific effects and their intensity can vary among individuals.
Are there risks associated with 3-MeO-PCMo use?Like many designer drugs, 3-MeO-PCMo may pose health risks, including physical and psychological effects. Its safety profile and long-term effects are not well-documented, so caution and moderation are advisable.
Is 3-MeO-PCMo for medical use?3-MeO-PCMo is not approved for medical use and is primarily encountered as a research chemical or designer drug.
Where can I find more information about 3-MeO-PCMo?Research articles, scientific journals, and online resources can provide more detailed information about 3-MeO-PCMo, its pharmacology, and its effects. Always consult reliable sources for accurate information.
References
Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (April 2011). “New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats”.This study explores the chemical synthesis of morpholine analogues related to phencyclidine (PCP) and their impact on pain perception in rats. The research provides insights into the pharmacological properties of these analogues.
Abiero A, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, et al. (March 2020). “4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels”.This research delves into the effects of 4-MeO-PCP and 3-MeO-PCMo, two dissociative drugs, on the mesolimbic dopamine pathway and the alteration of specific biomarkers. It sheds light on the rewarding and reinforcing properties of these substances.
Colestock T, Wallach J, Mansi M, Filemban N, Morris H, Elliott SP, et al. (February 2018). “Syntheses, analytical and pharmacological characterizations of the ‘legal high’ 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analogues”.This study focuses on the synthesis, analytical characterizations, and pharmacological properties of 3-MeO-PCMo, a “legal high,” and its analogues. It provides valuable information on these substances.
“3-MeO-PCMo”. New Synthetic Drugs Database.The New Synthetic Drugs Database contains information on various synthetic drugs, including 3-MeO-PCMo. It serves as a resource for understanding the characteristics and profiles of these substances.
Mitsuoka T, Hanamura K, Koganezawa N, Kikura-Hanajiri R, Sekino Y, Shirao T (September–October 2019). “Assessment of NMDA receptor inhibition of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay”.This research assesses the NMDA receptor inhibition properties of phencyclidine analogues using a high-throughput drebrin immunocytochemical assay. It offers insights into the pharmacological aspects of these substances.
